Homotypic Targeted Photosensitive Nanointerferer for Tumor Cell Cycle Arrest to Boost Tumor Photoimmunotherapy
Source abstract
Abstract
Recent advances in tumor immunotherapy mainly tend to remodel the immunosuppressive tumor microenvironment (TME) for immune enhancement. However, the complexity of TME makes it unlikely to achieve satisfactory therapeutic effects with any single intervention alone. Here, we focus on exposing intrinsic features of tumor cells to trigger direct pleiotropic antitumor immunity. We develop a photosensitive nanointerferer that is engineered with a nanoscale metal–organic framework decorated with tumor cell membranes for targeted delivery of a photosensitizer and small interfering RNA, which is used to knock down cyclin-dependent kinase 4 (Cdk4). Cdk4 blockade can arrest the cell cycle of tumor cells to facilitate antigen exposure and increase the expression level of programmed cell death protein ligand 1 (PD-L1). Under laser irradiation, photodynamic damage triggered by the nanointerferer induces the release of tumor antigens and recruitment of dendritic cells (DCs), thereby promoting the antitumor activity of CD8+ T cells in combination with anti-PD-L1 antibodies. Ultimately, these events markedly retard tumor progression in a mouse model of ectopic colon tumor with negligible adverse effects. This study provides an alternative treatment for effective antitumor immunity by exciting the intrinsic potential of tumor cells to initiate immune responses while reducing immune-related toxicities.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry, Wuhan University, Wuhan 430072, P. R. China
Institute for Advanced Studies, Wuhan University, Wuhan 430072, P. R. China
Wuhan Research Centre for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan 430071, P. R. China
Funding
Central University Basic Research Fund of China · National Natural Science Foundation of China
References (54)
Show source-provided references
1. 10.1146/annurev-cancerbio-030518-05555210.1146/annurev-cancerbio-030518-055552 ↗
2. 10.1016/j.cell.2017.01.01710.1016/j.cell.2017.01.017 ↗
3. 10.1056/NEJMra170348110.1056/NEJMra1703481 ↗
4. 10.1056/NEJMoa120069010.1056/NEJMoa1200690 ↗
5. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
6. 10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
7. 10.1002/adfm.20150128310.1002/adfm.201501283 ↗
8. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
9. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
10. 10.1002/adfm.20180468810.1002/adfm.201804688 ↗
11. 10.1007/s10118-021-2540-010.1007/s10118-021-2540-0 ↗
12. 10.1126/sciimmunol.aau658410.1126/sciimmunol.aau6584 ↗
13. 10.1002/advs.20180215710.1002/advs.201802157 ↗
14. 10.1002/adma.20210665410.1002/adma.202106654 ↗
15. 10.1002/anie.20211666910.1002/anie.202116669 ↗
16. 10.1021/jacs.8b0107210.1021/jacs.8b01072 ↗
17. 10.1002/adfm.20190244010.1002/adfm.201902440 ↗
18. 10.1038/ncomms997110.1038/ncomms9971 ↗
19. 10.2147/CMAR.S17185510.2147/CMAR.S171855 ↗
20. 10.1038/nrc260210.1038/nrc2602 ↗
21. 10.1016/j.bcp.2019.11367610.1016/j.bcp.2019.113676 ↗
22. 10.1038/nature2346510.1038/nature23465 ↗
23. 10.1038/nature2501510.1038/nature25015 ↗
24. 10.1016/j.cmet.2020.10.02110.1016/j.cmet.2020.10.021 ↗
25. 10.7150/thno.6582810.7150/thno.65828 ↗
26. 10.1021/ja408084j10.1021/ja408084j ↗
27. 10.31635/ccschem.020.20200020110.31635/ccschem.020.202000201 ↗
28. 10.1016/j.nantod.2012.06.01310.1016/j.nantod.2012.06.013 ↗
29. 10.1038/s41565-020-00843-710.1038/s41565-020-00843-7 ↗
30. 10.1021/nl500618u10.1021/nl500618u ↗
31. 10.1021/acsnano.9b0879810.1021/acsnano.9b08798 ↗
32. 10.1002/adfm.20190339110.1002/adfm.201903391 ↗
33. 10.1038/sj.gt.330048410.1038/sj.gt.3300484 ↗
34. 10.1016/j.nano.2016.02.00310.1016/j.nano.2016.02.003 ↗
35. 10.1021/jacs.6b0000710.1021/jacs.6b00007 ↗
36. 10.3390/pharmaceutics1204037110.3390/pharmaceutics12040371 ↗
37. 10.1038/s41467-021-26052-x10.1038/s41467-021-26052-x ↗
38. 10.1038/s41557-021-00854-410.1038/s41557-021-00854-4 ↗
39. 10.1038/nbt.261210.1038/nbt.2612 ↗
40. 10.1038/nbt.380210.1038/nbt.3802 ↗
41. 10.1021/acs.nanolett.0c0446810.1021/acs.nanolett.0c04468 ↗
42. 10.1038/nrg397810.1038/nrg3978 ↗
43. 10.1007/s12274-020-2954-y10.1007/s12274-020-2954-y ↗
44. 10.1093/annonc/mdz27810.1093/annonc/mdz278 ↗
45. 10.1158/0008-5472.CAN-17-221010.1158/0008-5472.CAN-17-2210 ↗
46. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
47. 10.1038/s41467-020-18745-610.1038/s41467-020-18745-6 ↗
48. 10.1002/adma.20180300110.1002/adma.201803001 ↗
49. 10.1038/nbt.169610.1038/nbt.1696 ↗
50. 10.1038/nrc318010.1038/nrc3180 ↗
51. 10.1038/s41586-020-2229-510.1038/s41586-020-2229-5 ↗
52. 10.1038/s41571-021-00473-510.1038/s41571-021-00473-5 ↗
53. 10.1007/s00262-011-1184-210.1007/s00262-011-1184-2 ↗
54. 10.1021/acsnano.7b0253310.1021/acsnano.7b02533 ↗